Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity

scientific article published on 5 May 2010

Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.DIABET.2010.02.001
P698PubMed publication ID20447851

P2093author name stringM Buysschaert
V Preumont
M-P Hermans
S Brichard
P433issue4
P921main subjectpreproinsulinQ7240673
P304page(s)293-298
P577publication date2010-05-05
P1433published inDiabetes and MetabolismQ15758385
P1476titleSix-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity
P478volume36

Reverse relations

cites work (P2860)
Q26829445Assessment of pancreatic β-cell function: review of methods and clinical applications
Q43769439Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study).
Q46869132Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy
Q36877205Evolution of exenatide as a diabetes therapeutic
Q52668530Exendin-4 modifies adipogenesis of human adipose-derived stromal cells isolated from omentum through multiple mechanisms.
Q37900151From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy
Q34586302Intensive therapy in newly diagnosed type 2 diabetes: results of a 6-year randomized trial
Q35493180Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes.
Q51373270The metabolic syndrome influences the response to incretin-based therapies.

Search more.